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Abstract 
Background: CD83, a cell surface glycoprotein that is stably expressed on mature dendritic cells, can be transiently 
induced on other hematopoietic cell lineages upon cell activation. In contrast to the membrane form of CD83, solu-
ble CD83 appears to be immunosuppressive. In an analysis of the phenotype of leukemic CD4+ T cells from patients 
with adult T-cell leukemia (ATL), we found that a number of primary CD4+ T cells became positive for cell surface 
CD83 after short-term culture, and that most of these CD83+ CD4+ T cells were positive for human T-cell leukemia 
virus type-I (HTLV-I) Tax (Tax1). We hypothesized that Tax1 is involved in the induction of CD83.
Result: We found that CD83 was expressed selectively on Tax1-expressing human CD4+ T cells in short-term cultured 
peripheral blood mononuclear cells (PBMCs) isolated from HTLV-I+ donors, including ATL patients and HTLV-I carriers. 
HTLV-I-infected T cell lines expressing Tax1 also expressed cell surface CD83 and released soluble CD83. CD83 can be 
expressed in the JPX-9 cell line by cadmium-mediated Tax1 induction and in Jurkat cells or PBMCs by Tax1 introduc-
tion via infection with a recombinant adenovirus carrying the Tax1 gene. The CD83 promoter was activated by Tax1 in 
an NF-κB-dependent manner. Based on a previous report showing soluble CD83-mediated prostaglandin E2 (PGE2) 
production from human monocytes in vitro, we tested if PGE2 affected HTLV-I propagation, and found that PGE2 
strongly stimulated expression of Tax1 and viral structural molecules.
Conclusions: Our results suggest that HTLV-I induces CD83 expression on T cells via Tax1 -mediated NF-κB activation, 
which may promote HTLV-I infection in vivo.
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Background
CD83 is a 40–50-kDa cell surface glycoprotein that is a 
member of the sialic-acid-binding immunoglobulin-like 
lectin family, and is a marker of mature dendritic cells 
(DCs) in humans and mice [1]. In contrast to mature 
DCs, which stably express high levels of CD83 [2], previ-
ous studies suggest that CD83 is transiently expressed on 
other hematopoietic cell lineages and tissues, including 
activated T cells and B cells [1, 3–5], macrophages [2], 
neutrophils [6], and NK cells [7] in vitro, and hematopoi-
etic tissues [8] and skin Langerhans cells [1] in vivo.
Two isoforms of CD83, a membrane-bound form 
(mCD83) and a soluble form (sCD83) have been iden-
tified; sCD83 is likely a result of shedding the mCD83 
isoform [9]. mCD83 critically functions not only in the 
development of CD4+ T cells in the thymus [8], but also 
in T cell activation [10] and the longevity of B and CD4+ 
T cells [4]. In contrast, sCD83 functions as a suppressor 
of T cell activation [11]. A recent study has shown that 
sCD83 suppresses the differentiation of DCs from mono-
cytes [12]. Elevated levels of plasma sCD83 have been 
demonstrated in patients with hematological malignan-
cies [13]. Kreiser et al. showed that the in vitro culture of 
mCD83-expressing fresh regulatory T cells in mice leads 
to the release of sCD83 [14]. Although the molecular 
mechanisms by which sCD83 mediates T cell suppression 
are not fully understood, human sCD83 may mediate its 
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inhibitory effect on T cell responses via prostaglandin E2 
(PGE2) produced by monocytes [15].
Human T-cell leukemia virus type-I (HTLV-I) is a 
human retrovirus that is etiologically associated with 
adult T-cell leukemia (ATL) [16] and HTLV-I-associated 
myelopathy/tropical spastic paraparesis (HAM/TSP) 
[17, 18]. The majority of HTLV-I carriers remain asymp-
tomatic throughout their lives, and approximately 5% 
of HTLV-I-infected individuals develop either ATL or 
HAM/TSP after prolonged latency periods [19]. HTLV-
I encodes Tax (Tax1), which activates viral transcrip-
tion and promotes mechanisms that are critical for cell 
growth and division, leading to viral replication [20]. 
The effects of Tax1 on cells include potent NF-κB activa-
tion, cell cycle perturbation, and cell transformation [21]. 
In addition to Tax1, the basic leucine zipper of HTLV-I 
(HBZ) has been proposed to play an important role in the 
oncogenesis of ATL by HTLV-I [22]. However, the pre-
cise mechanisms by which HTLV-I infection leads to dis-
ease development remain poorly understood.
HTLV-I is transmitted through contact with body flu-
ids containing infected cells; common examples include 
mother-to-child transmission [19]. It is difficult to detect 
HTLV-I-antigen-expressing cells in fresh PBMCs from 
HTLV-I infected individuals. When PBMCs are cultured 
for a short period of time, some T cells begin to produce 
HTLV-I antigens [23] followed by spontaneous immor-
talization of cells in cultures containing interleukin-2 
(IL-2) [24]. CD8+ cytotoxic T lymphocyte (CTL) [25] and 
neutralizing antibody [26] responses specific to HTLV-I 
play important roles in controlling HTLV-I propagation 
in HTLV-I carriers. It is noteworthy that not only ATL 
patients, but also healthy HTLV-I carriers are prone 
to immunodeficiency [27–31]. Curiously, monocytes 
from HTLV-I+ donors exhibit a deficiency in the ability 
to differentiate into mature DCs in  vitro, and cultured 
immature DCs show low levels of CD83 expression in 
association with poor T cell stimulation [32].
In an analysis of phenotypes of PBMCs from ATL 
patients and HTLV-I carriers living in Okinawa prefec-
ture, Japan, where ATL is prevalent, we detected high 
levels of CD83 expression in primary CD4+ T cells from 
PBMCs of HTLV-I+ donors after short-term in vitro cul-
ture. Surprisingly, most of these CD83+ cells from HTLV-
I+ donors were positive for Tax1. Herein, we show that 
Tax1 is responsible for the induction of CD83 on T cells, 
and discuss its possible role(s) in HTLV-I infection.
Results
CD83 expression on Tax1+ cells
In a phenotypic analysis of fresh and in  vitro cultured 
PBMCs from ATL patients in Okinawa, we noticed that 
short-term cultivation induced CD83 expression in a 
subpopulation of CD4+ T cells in PBMCs (Figure  1a, 
b). Interestingly, a majority of the CD83-positive CD4+ 
T cells exhibited detectable levels of intracellular Tax1 
expression. The Tax1 expression in cultured PBMCs from 
ATL patients was confirmed by a western blot analy-
sis with our anti-Tax1 monoclonal antibody (mAb) (Lt-
4) (Additional file  1: Figure  S1). Similar acquisition of 
CD83 on Tax1+ cells was observed in cultured PBMCs 
from HTLV-I carriers and HAM/TSP patients (data not 
shown). In contrast, only low levels of CD83 expression 
were observed in normal PBMCs cultured in vitro with-
out mitogen. Cultures with mitogen exhibited increased 
CD83 expression in a small population of CD3- PBMCs 
(Figure  1c), which were predominantly CD19+ (data 
not shown), indicating that those CD83+ cells were B 
lymphocytes.
We next examined CD83 expression with a panel of 
HTLV-I+ T cell lines. All of the Tax1+ cell lines tested, 
including the IL-2-independent T cell lines (MT-2, 
HUT102, and MT-1) and IL-2-dependent T cell lines 
derived from an ATL patient (ATL-026), a HAM/TSP 
patient (ILT-M1), or a healthy donor whose T cells were 
transformed in  vitro by HTLV-I (YT/cM1), were posi-
tive for CD83 (Figure  2a). It is noteworthy that an ATL 
patient-derived HTLV-I-infected T cell line that lacks 
Tax1 expression (TL-Om1) was negative for CD83 
expression. In addition, the HTLV-I+ rat T cell line 
W7TM-1, and the human HTLV-II+ T cell line Ton1 
were also positive for rat and human CD83, respec-
tively (Figure  2b). The HTLV-I-negative human T cell 
lines CEM, Molt-4, and Jurkat and the HIV-1-producing 
Molt4/IIIB were negative for CD83 (data not shown). 
CD83 expression thus appeared to parallel the expres-
sion of Tax1. These results suggest a relationship between 
CD83 and Tax1 expression.
The expression of CD83 in HTLV-I+ cells was con-
firmed by western blot analyses using our laboratory-
derived mAb (rat IgG, clone W83#8). As shown in 
Figure  3, the apparent molecular weight (MW) of the 
major CD83 molecule in HTLV-I+ HUT102 cells was 
48  kDa, which was comparable to that of ectopically 
expressed CD83 on 293T cells (293T/CD83). Since the 
protein core of CD83 has an estimated MW of 21  kDa 
and is heavily glycosylated [9], we inferred that the other 
CD83-specific bands ranging between 40 and 70 kDa may 
be CD83 isoforms with different levels of glycosylation.
We next examined the production of sCD83 by 
HTLV-I+ T cells. Levels of CD83 in cell lysates and cul-
ture supernatants were quantitated using a commercial 
enzyme-linked immunosorbent assay (ELISA) kit. All 
Tax1+ T cell lines tested produced readily detectable 
levels of sCD83 in culture supernatants (Figure  4). The 
relative levels of sCD83 were estimated at approximately 
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10–20% of CD83 levels associated with cells. Since 
plasma sCD83 is elevated in some patients with chronic 
lymphocytic leukemia [33], we attempted to determine 
the levels of sCD83 in plasma samples obtained from 
acute ATL patients. Out of 11 ATL samples, only one 
showed a significantly higher sCD83 level (>1,000 pg/ml) 
than normal (<20 pg/ml) (data not shown).
CD83 induction by Tax1
The potential ability of Tax1 to induce CD83 expression 
was examined using the Tax1-inducible human T cell 
line JPX-9. Incubation with CdCl2, which is required for 
Tax1 expression, induced apparent cell surface CD83 
expression on JPX-9 cells (Figure 5a). Importantly, CD83 
expression was predominantly restricted to Tax1+ cells. 
The majority of Tax1+ cells also expressed OX40, a rep-
resentative protein that is also induced by Tax1 on T cells 
[34].
To confirm the Tax1-mediated CD83 expression, CD83 
mRNA levels were quantitated by real-time PCR using 
peripheral blood mononuclear cells (PBMCs) and Jur-
kat cells following infection with recombinant adenovi-
rus encoding Tax1 (Figure 5b). CD83 mRNA levels were 
significantly elevated in both PBMCs and Jurkat cells. 
These results are consistent with the concept that Tax1 
induces cell surface expression of CD83, and suggest 
that the effect of Tax1 on CD83 expression occurs at the 
transcriptional level. Taken together, these data strongly 
imply that CD83 is a member of the HTLV-I Tax-induci-
ble protein family.
Enrichment of live Tax1+ and Tax1− cells by cell sorting
It may be noteworthy that the triple-positive (Tax1+ 
CD83+ OX40+) phenotype was found in primary CD4+ 
T cells from an ATL patient (Figure  6). Generally, IL-
2-dependent HTLV-I-infected T cell lines derived from 
HTLV-I+ donors consist of HTLV-I antigen-positive 
and -negative cells, especially during the early culture 
stage with low passages. Flow cytometry-based cell 
sorting cannot separate live Tax1+ cells from live Tax1− 
cells owing to intracellular localization of Tax1. Based 
on the present finding that most Tax1+ cells expressed 
both CD83 and OX40, we attempted to sort live Tax1+ 
and Tax1− cells. An IL-2 dependent HTLV-I+ T cell line 
(OKH4) from a HAM/TSP patient was stained with anti-
OX40 and anti-CD83 mAbs, and subjected to cell sort-
ing. CD83+ OX40+ sorting efficiently enriched the Tax1+ 
cell population (Figure  7). Similar enrichment of Tax1+ 
cells was obtained with three IL-2-dependent HTLV-I+ T 
cell lines (data not shown). This strategy would be useful 
for further studies on Tax1 function in pHTLV-I-infected 
primary T cells.
Figure 1 Flow cytometric analysis (FCM) of CD83 expression on primary CD4+ T cells expressing Tax1. a, b Lymphocytes were gated based on FSC 
and SSC in peripheral blood mononuclear cells (PBMCs) derived from adult T cell leukemia (ATL) patients (ATL# 1 to #5) and examined for expression 
of CD83 and Tax1 before or after a 1-day culture. Most ATL patient-derived PBMCs consisted of leukemic CD4+ T cells (data not shown). c Lympho-
cytes in PBMCs from normal donors were examined for CD83 expression after a 1-day culture in the presence or absence of phytohemagglutinin 
(PHA). Representative profiles are displayed.
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Tax1‑responsive elements in the CD83 promoter
To gain insight into the molecular mechanism of Tax1-
dependent induction of CD83, the CD83 promoter was 
examined by reporter assays. Jurkat cells were trans-
fected with a luciferase reporter plasmid, pCD83(-537)
Luc, carrying the isolated wild-type CD83 promoter 
along with the Tax1 expression plasmid. The CD83 pro-
moter was profoundly activated by Tax1 (Figure  8a). In 
efforts to localize the CD83 promoter sequences with 
biological activity, reporter assays were performed using 
a series of 5′ deletion constructs of the CD83 promoter. 
These studies showed that pCD83(-101)Luc retained 
activity to promote transcription in response to Tax1, 
similar to pCD83(-537)Luc, while pCD83(-29)Luc did 
not respond to Tax1 (Figure 8a). The observations indi-
cate that a Tax1-responsive element(s) in the CD83 pro-
moter is located in the region between −101 and −30. 
A computer search identified two possible NF-κB bind-
ing sites between the −101 to −30 region of the CD83 
promoter (Figure  8b). We next investigated the poten-
tial role of those NF-κB binding sites in Tax1-mediated 
activation of CD83 gene transcription. This objective was 
achieved using substitution mutations that were intro-
duced to either each of the possible NF-κB binding sites 
or to both sites (Figure  8c). Upon expression of Tax1, 
each single mutant showed an approximate 50% decrease 
in promoter activity compared with the wild-type CD83 
promoter (Figure 8d). Little, if any, response to Tax1 was 
observed for the mutant pCD83(-537 κBmt1/2)Luc car-
rying mutations at both sites (Figure 8d).
The Tax1-mediated upregulation of CD83 expression 
via NF-κB activation was verified by reporter assays on 
a series of Tax1 mutants. All Tax1 mutants except for 
TaxM22, which lacks the NF-κB activation function, 
facilitated CD83 promoter activity (Figure  9). TaxM22 
did not show significant induction of luciferase activity 
from pCD83(-537)Luc. Collectively, these results dem-
onstrate that the two NF-κB binding sites are critical for 
the induction of CD83 expression in response to Tax1. 
HTLV-II Tax2B also upregulated CD83 promoter activ-
ity, consistent with cell surface expression of CD83 by the 
HTLV-II+ cells (Figure 2b).
Figure 2 CD83 expression on HTLV-I+ and HTLV-II+ T-cell lines. a HTLV-I+ T cell lines (MT-2, HUT102, MT-1, and TL-Om1), and IL-2-dependent T cell 
lines generated from an ATL patient (ATL-026, CD4+), a HAM/TSP patient (OKH4, CD8+), and a normal donor (in vitro-transformed YT/cM1, CD4+) 
were examined for CD83 and Tax1 expression by FCM. Note that the TL-Om1 cell line is negative for Tax1. b Rat and human CD83 expression levels 
on the rat CD4+ Tax1+ T cell line (W7TM-1) and the human HTLV-II+ T cell line (Ton1), respectively, were analyzed by FCM.
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Stimulation of Tax1 expression and HTLV‑I production 
by PGE2
sCD83 has been reported to stimulate PGE2 production 
from human monocytes and to suppress T cell activa-
tion in vitro [15]. We thus tested the effects of PGE2 on 
HTLV-I expression in an ATL-derived HTLV-I+ T cell 
line (ATL-056). PGE2 induced marked expression of 
Tax1 (Figure  10a). In addition, we observed an increase 
in expression of the viral envelope protein gp46 and 
release of viral core protein p24 to the culture superna-
tants (Figure 10a). Figure 10b shows that PGE2 treatment 
increased the syncytium-inducing activity of ATL-056 
cells, suggesting that PGE2 enhances cell-to-cell infectiv-
ity of HTLV-I.
Discussion
In the present study, we showed for the first time that 
CD83 is expressed by Tax1+ cells in primary cultures of 
CD4+ T cells and HTLV-I- or HTLV-II-infected CD4+ 
or CD8+ T cell lines. Fresh ATL leukemic T cells express 
CD2, CD5, CD4, CD25, CD29, CD40RO, CD194, T cell 
receptor α/β, and HLA-DR with diminished CD3 expres-
sion [35], but they do not express Tax1. Cultures of pri-
mary CD4+ T cells from HTLV-I+ donors and HTLV-I+ 
T cell lines express additional cell surface markers 
including the T cell activation markers (CD40, CD80, 
and CD86), TNF/TNFR family members (GITR, 4-1BB, 
4-1BBL, OX40, and OX40L), the chemokine receptors/
interleukin receptors (CCR7 and CCR8), and a number 
of cell adhesion molecules, such as CD58/LFA3, CD54/
ICAM-1, and VCAM-1. Some of those molecules are 
induced by Tax1 [36], and the present study adds CD83 
to the list of members of the HTLV-I and -II Tax-induci-
ble protein family.
Tax1 is a transcriptional modulator that lacks the abil-
ity to directly bind to DNA elements; rather, it modifies 
cellular transcription factor activity, in particular via 
NF-κB, CREB, and SRF. Among these factors, NF-κB 
attenuated by Tax1 is critically involved in immor-
talization and transformation. The present study dem-
onstrates that Tax1-mediated induction of CD83 is 
absolutely dependent on the NF-κB pathway, similar to 
that reported for OX40 [34] and OX40L [36]. It has been 
reported that the Epstein-Barr virus latent membrane 
protein 1 (LMP1), which is known to activate the NF-κB 
pathway, also induces CD83 expression in human B lym-
phocytes, in which an NF-κB binding site in the CD83 
promoter is responsive for LMP1-mediated activation 
[37]. Our present study revealed that another NF-κB 
binding site in the CD83 promoter was responsive to 
Figure 3 Western blot analysis of CD83 expressed in the HTLV-I+ 
T cell line HUT102. Cell lysates from control 293T/CT (lanes 1 and 5), 
CD83-transfected 293/TCD83 (lanes 2 and 6), CEM (lanes 3 and 7), and 
HUT102 (lanes 4 and 8) were subjected to sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) on a 5–20% gel, and 
blotted onto PVDF membranes. The membranes were incubated 
with either rat anti-human CD83 monoclonal antibody (mAb) (clone 
W#83-8, lanes 1–4) or isotype control rat IgG (clone WAP-24, lanes 5–8) 
antibody, followed by treatment with HRP-labeled goat anti-rat IgG 
antibody.
Figure 4 Quantitation of cell-associated CD83 and sCD83. The 
HTLV-I+ T cell lines (MT-2 and HUT-102) and T cell lines from either 
ATL patients (ATL-026, ATL-056, ATL-084, ILT-H2) or a HAM/TSP patient 
(OKH4) were cultured in a volume of 1 ml/well for 3 days in vitro. Cells 
and culture supernatants were separated by centrifugation, and the 
cells were lysed with 1 ml of a lysing buffer. The levels of CD83 in the 
culture supernatants or in the cell lysates were determined by ELISA. 
Results are shown as the mean ± SD of CD83 of triplicate cultures.
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NF-κB activated by Tax1 in human T cells. It is of inter-
est that the activation of NF-κB is insufficient for CD83 
induction since a TL-Om1 cell line that contains a sin-
gle copy of the HTLV-I provirus, but does not express 
Tax1, was negative for CD83 expression (Figure 2), while 
NF-κB in TL-Om1 is constitutively activated [38]. Thus, 
Tax1 expression may determine the promoter binding 
specificity and/or transcriptional regulation of NF-κB 
target genes such as CD83, OX40, and OX40L. Further 
studies are required to clarify the additional require-
ments for CD83 induction by Tax1.
The potential for CD83 induction by Tax1 in HTLV-I 
infections that leads to leukemogenesis or the onset of 
a neurological disorder, remains unknown. So far, CD83 
modulation has been linked to virus escape from the T 
cell immune system. For example, human cytomegalovi-
rus (HCMV) infection of DCs has been shown to inhibit 
T cell stimulation via release of sCD83 [39], and human 
herpes simplex virus (HSV) infection of mature DCs has 
been shown to downregulate the cell surface expression 
of CD83 by degradation of CD83 via the cellular pro-
teasome [40]. Because the expression of either Tax1 or 
CD83 on CD4+ T cells is difficult to detect and moni-
tor in the peripheral blood, even in acute ATL patients 
(Figure  1), Tax1-induced CD83 seems to be indirectly 
associated with the onset of ATL or HAM/TSP. How-
ever, observations of the steady presence of strong CTL 
and high levels of antibody responses specific for HTLV-
I antigens in HTLV-I+-infected individuals indicate the 
persistent production of HTLV-I in vivo. In addition, an 
immunodeficiency was found in ATL patients or healthy 
carriers [27–31], and the inability of monocytes from 
HTLV-I+ donors to differentiate into mature DCs has 
been reported [32]. Integration of these results may pro-
vide some clues regarding the roles of CD83 in HTLV-I 
infection. First, Bates et  al. recently reported that the 
homotypic interaction of mCD83 via cell-to-cell contact 
inhibits pro-inflammatory responses (including IL-12 
production) induced by DCs [41]; accordingly, mCD83 
induced on HTLV-I+ CD4+ T cells may interact with 
mCD83 on immuno-stimulated DCs in vivo and suppress 
IL-12 production, presumably resulting in inhibition of 
anti-HTLV-I Th1 responses. Second, sCD83 released 
from Tax1+ CD4+ T cells may interact with monocytes 
Figure 5 Induction of CD83 expression by Tax1. a CD83 and Tax1 co-expression (Panel 1), OX40 and Tax1 co-expression (Panel 2), and OX40 and 
CD83 co-expression (Panel 3) in JPX-9 cells were examined by FCM. Cells were cultured either in medium alone (upper columns) or in the presence 
of 10 μM CdCl2 (lower columns) for 3 days. b PBMCs and Jurkat cells were infected with recombinant Tax1 adenovirus (Ad-Tax1) or wild-type virus 
(Ad-Con), cultured for 48 h and harvested for mRNA isolation. The levels of CD83 mRNA were measured by quantitative PCR with specific primers 
indicated in the Methods section. The results are shown as the mean ± SE after normalization against 18S rRNA.
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and stimulate the production of the pleotropic bioregu-
lator PEG2. PEG2 has been reported to enhance HTLV-
I gag p19 production from PBMC cultures of HTLV-I 
carriers [42] and to stimulate HTLV-I LTR in combina-
tion with CD3/CD28 activation in human T cell lines 
[43]. Consistent with these observations, we showed in 
the present study that PGE2 alone enhanced the expres-
sion of HTLV-I Tax1 and HTLV-I-mediated cell fusion 
(Figure 10). Therefore, it can be speculated that sCD83-
induced PGE2 from monocytes stimulates HTLV-I pro-
duction and the expansion of HTLV-I+ CD4+ T cells via 
the induction of Tax1 expression in a paracrine manner. 
However, our preliminary experiments failed to show 
that soluble recombinant CD83 actually enhances HTLV-
I infection in  vitro via production of PGE2 from pri-
mary monocytes. Further studies to test our hypotheses, 
including the link between T-cell activation by mCD83 
and enhanced HTLV-I infection, are in progress.
Since normal human T cells express low to undetect-
able levels of CD83, high expression of both CD83 and 
OX40 on a single CD4+ T cell is a good marker of intra-
cellular Tax1 expression. The sorting method for cells 
directly stained with anti-Tax antibody does not enable 
enrichment for live Tax1+ cells due to the required fixa-
tion and permeabilization of cells [44]. Thus, the present 
findings could provide a useful method for the enrich-
ment of live Tax1+ T cells, as shown in Figure  7, and 
presumably will contribute to further studies on Tax1 
function in the development and maintenance of HTLV-
I-related diseases.
Conclusions
The present study documents the potential role of HTLV-
I Tax in the induction of CD83 cell surface expression 
and release of sCD83 in an NF-κB-dependent manner in 
human CD4+ T cells in vitro, which may indirectly sup-
press immune responses and promote HTLV-I infection 
in vivo in terms of virus transmission to new target cells 
and expansion and/or survival of infected T cell clones.
Methods
Reagents
The medium used throughout was RPMI 1640 medium 
(Sigma-Aldrich. Inc., St. Louis, MO, USA) supplemented 
with 10% fetal calf serum (FCS), 100  U/ml penicillin 
and 100  µg/ml streptomycin (hereinafter called RPMI 
medium). Mouse monoclonal antibodies (mAbs) specific 
for HTLV-I Tax (clone Lt-4), OX40 (clone B-7B5), and 
KLH (IgG3, clone KLH-3, Tanaka et  al., unpublished) 
were purified in our laboratory from ascites fluids of 
CB.17-SCID mice carrying the appropriate hybridomas. 
The ascites fluid samples were subjected to ammonium 
sulfate precipitation followed by gel filtration with Super-
dex G-200 (GE Healthcare, Tokyo, Japan). mAbs were 
Figure 6 Co-expression of CD83 and OX40 on Tax1+ T cells. PBMCs of an ATL patient (#6) were cultured for 18 h and stained with antibodies 
against CD4, Tax1, CD83 and OX40. CD4+ Tax1− cells and CD4+ Tax1+ T cells were gated and examined for their expression of CD83 and OX40 by 
FCM.
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labeled with either fluorescein isothiocyanate (FITC) 
or HiLyte Fluor™ 647 using commercial labeling kits 
(Dojindo, Kumamoto, Japan) according to the manufac-
turer’s instructions. FITC-, PE- or PE-Cy7-labeled mouse 
mAbs against human CD3, CD4, CD8, CD14, CD19, 
CD56, and CD83 (clone H15e), and FITC-labeled goat 
anti-rat IgG, donkey anti-rabbit IgG, and HRP-labeled 
goat anti-rat IgG antibodies were purchased from BioLe-
gend (Tokyo, Japan). Rabbit polyclonal IgG anti-rat CD83 
antibody was obtained from Sino Biological (Beijing, 
China). Prostaglandin E2 (PGE2) was purchased from 
Sigma-Aldrich. Inc., (St. Louis, MO, USA).
Cell cultures
The protocols for the use of human PBMCs and animals 
were approved by the Human IRB and the Institutional 
Animal Care and Use Committee (IACUC) on clinical 
and animal research of the University of the Ryukyus 
and Tokyo Medical and Dental University prior to the 
initiation of the study. All human samples were col-
lected after obtaining written informed consent accord-
ing to the Declaration of Helsinki. PBMCs were isolated 
from heparinized blood by a standard density gradient 
centrifugation [26]. HTLV-I-producing T cell lines 
were IL-2-independent T cell lines (MT-1, MT-2, and 
HUT102), IL-2-dependent CD4+ and CD8+ T cell lines 
derived from various HTLV-I+ donors (ATL patients, 
HAM/TSP patients, or asymptomatic HTLV-I carri-
ers), and CD4+ T cell lines derived from normal PBMCs 
established by co-cultivation with mitomycin C-treated 
HTLV-I-producing cells [26]. The TL-Om1 cell line is an 
ATL-patient-derived IL-2-independent HTLV-I-infected 
T cell line not expressing the Tax antigen [38]. The 
HTLV-I+ rat T cell line was W7TM-1 [45]. The HTLV-
I-negative human T cell lines were Jurkat, CEM, Molt-4, 
Molt-4/IIIB, and Jurkat-derived JPX-9, in which Tax1 can 
be induced by cultivation in the presence of 10 μM CdCl2 
[46]. The HTLV-II+ human T cell line was Ton1 [47]. 
Cell lines were cultured in RPMI medium in the pres-
ence of 20  U/ml recombinant human IL-2, if necessary. 
For select experiments, human PBMCs were stimulated 
with 10 μg/ml phytohemagglutinin (PHA) (Wako, Japan) 
or immobilized anti-CD3 and anti-CD28 mAbs (BioLeg-
end). Derivatives of 293T cells expressing human CD83 
(293T/CD83) and its vector control (293T/CT) were 
established in our laboratory by transfection of 293T 
Figure 7 Flow cytometric analysis of Tax1 expression of cell sorter purified CD83hi/OX40hi and CD83negative/OX40negative populations. An IL-2 
dependent HTLV-I+ T cell line generated from a HAM/TSP patient (OKH4) was stained with anti-OX40 and anti-CD83 mAbs. The CD83+OX40+ and 
CD83−OX40− populations were sorted, and stained for Tax1. The Tax1 expression profiles prior to and post sorting are shown.
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cells with human CD83 vector (pCAGIPuro/CD83) and 
empty vector (pCAGIPuro), respectively.
Syncytium induction assay was performed using a 
combination of ILT-M1 and Jurkat cells as described pre-
viously [26].
Generation of a new anti‑CD83 mAb
Hybridomas producing mAbs against human CD83 were 
generated from spleen cells of WKA rats immunized with 
recombinant human CD83-Fc fusion protein (R&D Sys-
tems, Inc., Cosmo Bio, Tokyo, Japan) by cell fusion with 
the SP2/0 myeloma cell line utilizing the Sendai virus 
cell fusion kit (GenomeONE, Cosmo Bio), and screened 
by ELISA using CD83-Fc-coated plates (0.1  μg/ml per 
well) and goat anti-rat IgG-HRP antibody (BioLegend). 
mAbs were further selected based on their abilities to 
stain CD83 expressed on 293T/CD83 cells but not 293T/
CT cells. Western blots were performed as reported pre-
viously [48]. The anti-CD83 mAbs established by this 
screening included clones W83#4 and W83#8, both of 
which were rat IgG2b and applicable for flow cytometry. 
The clone W83#4, but not W83#8, competed in a binding 
assay with a commercially available mouse anti-human 
CD83 mAb clone H15e. The clone W83#8, but not 
W83#4 or H15e, was applicable for western blot analysis 
(data not shown).
Figure 8 Tax1-responsive elements in the CD83 promoter. a Luciferase reporter plasmids carrying the wild-type (−537 to +41) and its 5′ deletion 
mutants (−285 to +41, −146 to +41, −101 to +41, and −29 to +41) of the CD83 promoter were transfected into Jurkat cells along with the 
Tax1 expression plasmid (pMT-2Tax). Cells were cultured for 48 h and analyzed for luciferase activity. The results were normalized based on protein 
content. b Nucleotide sequences of the CD83 promoter (−101 to −1 with respect to the transcription start site). Possible NF-κB binding sites (NF-
κB1 and NF-κB2) are underlined. c Schematic representation of the possible NF-κB binding sites in the CD83 promoter is shown with lowercase 
letters indicating mutated sequences. d Reporter plasmids carrying the wild-type CD83 promoter or mutant promoter were transfected into Jurkat 
cells along with the Tax1 expression plasmid (pMT-2Tax). Cells were cultured for 48 h and analyzed for luciferase assay. The results shown are as the 
mean ± SE after normalization based on protein content.
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Flow cytometry (FCM), cell sorting, and ELISA
Phenotypic analyses of cells were carried out using 
polychromatic flow cytometry (FCM) as reported pre-
viously [26]. Briefly, live cells were Fc-blocked with 
2  mg/ml pooled normal human IgG in FACS buffer 
[PBS containing 0.2% bovine serum albumin (BSA) and 
0.1% sodium azide] for 10 min on ice, followed by incu-
bation with fluorescent-dye labeled mAbs for 30  min. 
After washing with FACS buffer, the cells were fixed in 
4% paraformaldehyde (PFA) in PBS for 5  min at room 
temperature followed by permeabilization and washing 
in FACS buffer containing 0.5% saponin and 1% BSA 
(Sigma). An aliquot of the stained cells was incubated 
with 0.1  μg/ml HiLyte Fluor™ 647-labeled anti-Tax1 
antibody (clone Lt-4) for 30 min. Negative control cells 
were stained with HiLyte Fluor™ 647-labeled Lt-4 in the 
presence of 100 μg/ml unlabeled Lt-4. These cells were 
analyzed using a FACSCalibur (BD, Franklin Lakes, NJ, 
USA) and data obtained were analyzed using the Cell 
Quest software (BD).
To sort CD83 and OX40 double-positive and double-
negative cell populations, IL-2-dependent T cell lines 
established from HTLV-I+ donors were stained with 
PE-Cy7-labeled anti-CD83 (clone H15e) and PE-labeled 
anti-OX40 (clone B-7B5) mAbs, and then subjected to 
sorting using a cell sorter SH800Z (Sony, Tokyo, Japan) 
equipped with appropriate filters for multi-color analysis 
in a dual semiconductor laser (488)/(639 nm) system.
sCD83 in culture supernatants and cell lysates were 
quantitated using a commercial ELISA kit (MyBiosource, 
San Diego, CA, USA). HTLV-I p24 production into the 
culture supernatants was determined by our in-house 
formulated ELISA [26].
Plasmids
Expression plasmids for Tax1 (pMT-2Tax), Tax2B 
(pHβAP-r1-neo Tax2B), and Tax1 mutants were derived 
using the pHβAP-r-1-neo system with the human 
β-actin promoter [49, 50]. Tax1 mutants lacking the 
ability to activate NF-κB (TaxM22), CREB (Taxd3), and 
SRF (Tax703) in T cells have been described previously 
[50]. The luciferase reporter plasmids for the NF-κB 
site (pκB-Luc), CREB binding site (pLTR-Luc), and 
CArG box (pCArG-Luc) have been described elsewhere 
[51–53]. The CD83 reporter plasmid [pCD83(-537)Luc] 
was generated by insertion of a 578-bp fragment (−537 
to +41 from the transcription start site [54]) ampli-
fied from human genomic DNA by PCR using forward 
Figure 9 NF-κB-dependent activation of the CD83 promoter by Tax1. Jurkat cells were transfected with either Tax1, Tax2B, or its mutant plasmid 
along with the wild-type CD83 promoter reporter plasmid, cultured for 48 h, and then assayed for luciferase activity. The activities of the Tax expres-
sion plasmids utilized were confirmed based on their ability to induce cognate transcription factors under our experimental conditions. The results 
shown are the mean ± SE after normalization based on protein content.
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(5′-acgctagccatggaaatctaacgcgccttt-3′) and reverse (5′-gtaa 
gcttggctggagcgctgcgccgctgc-3′) primer pairs. The insert 
was cloned into the NheI and HindIII sites of the pGL3-
basic vector. A series of 5′ deletion mutants of the human 
CD83 promoter was generated by PCR and inserted into 
pGL3-basic, yielding pCD83(-285)Luc, pCD83(-146)Luc, 
pCD83(-101)Luc, and pCD83(-29)Luc. The substitution 
mutants of the two possible NF-κB binding sites in the 
CD83 promoter were generated by PCR using the mutant 
primers, yielding pCD83(-537 κBmt1)Luc, pCD83(-537 
κBmt2)Luc, and pCD83(-537 κBmt1/2)Luc with muta-
tions at the NF-κB1 site, NF-κB2 site, and both sites, 
respectively (see Figure 8c, d).
Infection with adenoviruses
Recombinant adenovirus for Tax1 (Ad-Tax1) [55] was 
generated with the ViraPower adenoviral expression sys-
tem with the CAG promoter according to the supplier’s 
instructions. PBMCs and Jurkat cells were infected at 
an MOI of 100 or 10 plaque forming units (PFU)/cell, 
respectively, as previously described [56, 57].
Quantitative PCR
Total RNA was extracted using Isogen (Nippon Gene 
Co. Ltd., Tokyo, Japan) according to the supplier’s pro-
tocol. First-strand cDNA was synthesized using the first-
strand cDNA synthesis kit for reverse transcription-PCR 
(AMV; Roche, Tokyo, Japan). Quantification of CD83 
gene expression was performed utilizing the forward 
(5′-gcgacgccggaggtgaaggtg-3′) and reverse (5′-tccc-
cgagttgcagctggtagtgt-3′) primer pair using a LightCycler 
(Roche). The 18S rRNA primers were obtained from 
TaKaRa (Shiga, Japan).
Reporter assay
Jurkat cells were transfected with Tax expression plasmids 
along with reporter plasmids by the DEAE-dextran method 
described previously [58]. Cell lysates were prepared for 
determination of luciferase activity using the luciferase 
assay system (Promega, Tokyo, Japan) according to the 
manufacture’s recommendations. Normalization of lucif-
erase activity was performed against the cell lysate protein 
concentration that was measured by the DC Protein Assay 
Figure 10 Enhancement of Tax1 expression and HTLV-I infectivity by prostaglandin E2 (PGE2). a ATL-patient-derived IL-2-dependent CD4+ T cell 
lines (ATL-056i and ATL-003i) were cultured in the presence or absence of 100 ng/ml PGE2 for 24 h and examined for the expression of Tax1 and 
HTLV-I envelope gp46 antigen by FCM. The levels of HTLV-I gag p24 released into the culture supernatants were determined by ELISA and are 
shown on the  top of the dot plot. b ATL-056i cells suspended at 1 × 106 cells/ml either untreated or treated with PGE2 for 24 h were co-cultured 
with an equal volume of Jurkat cells (1 × 106 cells/ml) for an additional 18 h in triplicate wells. Then, the numbers of syncytia (per ml) were counted 
manually as described previously [26].
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Kit (Bio-Rad, Tokyo, Japan). The assays were repeated at 
least three times and the mean ± SE values are shown.
Statistical analysis
A paired t-test was performed for statistical analysis. 
P-values of less than 0.05 were considered significant.
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